Evidence map›Paper›PMID 34484217›Full record

ArticleFrontiers in immunology2021

Lygia Bertalha Yaegashi, Camila Machado Baldavira, Tabatha Gutierrez Prieto, Juliana Machado-Rugolo, Ana Paula Pereira Velosa, Lizandre Keren Ramos da Silveira, Aline Assato, Alexandre Muxfeldt Ab'Saber, Roberto Falzoni, Teresa Takagaki and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Lygia Bertalha YaegashiDepartment of Pathology, University of São Paulo Medical School, São Paulo, Brazil.
Camila Machado BaldaviraDepartment of Pathology, University of São Paulo Medical School, São Paulo, Brazil.
Tabatha Gutierrez PrietoDepartment of Pathology, University of São Paulo Medical School, São Paulo, Brazil.
Juliana Machado-RugoloDepartment of Pathology, University of São Paulo Medical School, São Paulo, Brazil.
Ana Paula Pereira VelosaRheumatology Division of the Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil.
Lizandre Keren Ramos da SilveiraRheumatology Division of the Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil.
Aline AssatoDepartment of Pathology, University of São Paulo Medical School, São Paulo, Brazil.
Alexandre Muxfeldt Ab'SaberDepartment of Pathology, University of São Paulo Medical School, São Paulo, Brazil.
Roberto FalzoniDepartment of Pathology, University of São Paulo Medical School, São Paulo, Brazil.
Teresa TakagakiDivision of Pneumology, Instituto do Coração (Incor), University of São Paulo Medical School (USP), São Paulo, Brazil.
Pedro Leme SilvaLaboratory of Pulmonary Investigation, Carlos Chagas Filho Biophysics Institute, Federal University of Rio de Janeiro, Centro de Ciências da Saúde, Rio de Janeiro, Brazil.
Walcy Rosolia TeodoroRheumatology Division of the Hospital das Clinicas, University of São Paulo Medical School, São Paulo, Brazil.
Vera Luiza CapelozziDepartment of Pathology, University of São Paulo Medical School, São Paulo, Brazil.
Universidade de São Paulo · BRUniversidade Federal do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-small cell lung carcinoma (NSCLC) is a complex cancer biome composed of malignant cells embedded in a sophisticated tumor microenvironment (TME) combined with different initiating cell types, including immune cells and cancer-associated fibroblasts (CAFs), and extracellular matrix (ECM) proteins. However, little is known about these tumors' immune-matricellular relationship as functional and mechanical barriers. This study investigated 120 patients with NSCLC to describe the immune-matricellular phenotypes of their TME and their relationship with malignant cells. Immunohistochemistry (IHC) was performed to characterize immune checkpoints (PD-L1, LAG-3, CTLA-4+, VISTA 1), T cells (CD3+), cytotoxic T cells (CD8

Indexed as

Biomarkers, TumorAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungDisease ProgressionDisease SusceptibilityFemaleGene Expression RegulationHumansImmunohistochemistryKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm GradingBiomarkers, Tumorcancer-associated fibroblastscollagenimmune cellsimmunofluorescenceimmunohistochemistrylung cancernon-small cell lung cancer

Identifiers

PMID34484217
PMCPMC8415570
OpenAlexW3194877482

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.